These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 27426246)
1. [Toxicity associated with EGRF inhibition: review and key aspects in the management of afatinib]. Taus Á Med Clin (Barc); 2016 Apr; 146 Suppl 1():30-5. PubMed ID: 27426246 [TBL] [Abstract][Full Text] [Related]
2. [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment]. Cobo M; Gutiérrez V; Rodelo L; López O; Ruiz M; Godoy A Med Clin (Barc); 2016 Apr; 146 Suppl 1():25-9. PubMed ID: 27426245 [TBL] [Abstract][Full Text] [Related]
3. [Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation]. Vidal ÓJ Med Clin (Barc); 2016 Apr; 146 Suppl 1():12-8. PubMed ID: 27426243 [TBL] [Abstract][Full Text] [Related]
4. [Mechanism of action and preclinical development of afatinib]. Diz Taín P; González AL; García-Palomo A Med Clin (Barc); 2016 Apr; 146 Suppl 1():7-11. PubMed ID: 27426242 [TBL] [Abstract][Full Text] [Related]
5. [Evidence on afatinib in patients progressing on a first-line treatment]. Artal Cortés Á; Gimeno Pelegrín J; Alejandro MÁ Med Clin (Barc); 2016 Apr; 146 Suppl 1():19-24. PubMed ID: 27426244 [TBL] [Abstract][Full Text] [Related]
6. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer. Marquez-Medina D; Popat S Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834 [TBL] [Abstract][Full Text] [Related]
7. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer. Engle JA; Kolesar JM Am J Health Syst Pharm; 2014 Nov; 71(22):1933-8. PubMed ID: 25349236 [TBL] [Abstract][Full Text] [Related]
8. Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme. Khan F; Ottensmeier C; Popat S; Dua D; Dorey N; Ellis S; Szabo M; Upadhyay S; Califano R; Chan S; Lee L; Ali CW; Nicolson M; Bates AT; Button M; Chaudhuri A; Mulvenna P; Shaw HM; Danson SJ Eur J Cancer; 2014 Jul; 50(10):1717-1721. PubMed ID: 24726055 [TBL] [Abstract][Full Text] [Related]
9. New kinase inhibitor approved for metastatic lung cancer. Thompson CA Am J Health Syst Pharm; 2013 Aug; 70(16):1363. PubMed ID: 23903470 [No Abstract] [Full Text] [Related]
10. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. Hirsh V BioDrugs; 2015 Jun; 29(3):167-83. PubMed ID: 26123538 [TBL] [Abstract][Full Text] [Related]
12. Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer. Keating GM Drugs; 2014 Feb; 74(2):207-21. PubMed ID: 24435321 [TBL] [Abstract][Full Text] [Related]
13. The safety of afatinib for the treatment of non-small cell lung cancer. Barron F; de la Torre-Vallejo M; Luna-Palencia RL; Cardona AF; Arrieta O Expert Opin Drug Saf; 2016 Nov; 15(11):1563-1572. PubMed ID: 27633264 [TBL] [Abstract][Full Text] [Related]
14. [A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker]. Wislez M; Malka D; Bennouna J; Mortier L; Bensadoun RJ; Sicard J; Dielenseger P; Rey JB; Moro-Sibilot D; Scotté F Bull Cancer; 2014 Jun; 101(6):647-52. PubMed ID: 24977454 [TBL] [Abstract][Full Text] [Related]
15. Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience. Kudo K; Hotta K; Bessho A; Nogami N; Kozuki T; Kuyama S; Inoue K; Harita S; Okada T; Gemba K; Fujii M; Takigawa N; Oda N; Tanimoto M; Kiura K Cancer Chemother Pharmacol; 2016 May; 77(5):1005-9. PubMed ID: 27029623 [TBL] [Abstract][Full Text] [Related]
16. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors. Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M; Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527 [TBL] [Abstract][Full Text] [Related]
17. NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer. Dillon B; Naidoo B; Knight H; Clark P Lancet Oncol; 2012 Aug; 13(8):764-5. PubMed ID: 23024988 [No Abstract] [Full Text] [Related]
18. [Afatinib (BIBW 2992)]. Prim N; Fore M; Mennecier B Rev Pneumol Clin; 2014 Oct; 70(5):279-85. PubMed ID: 24878189 [TBL] [Abstract][Full Text] [Related]
19. Clairvoyance or reliable prediction of the future? van Zandwijk N; van de Vijver MJ Ann Oncol; 2007 Mar; 18(3):407-8. PubMed ID: 17322538 [No Abstract] [Full Text] [Related]
20. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Murakami H; Tamura T; Takahashi T; Nokihara H; Naito T; Nakamura Y; Nishio K; Seki Y; Sarashina A; Shahidi M; Yamamoto N Cancer Chemother Pharmacol; 2012 Apr; 69(4):891-9. PubMed ID: 22071596 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]